Hong Kong stock movement: CF PHARMTECH benefits from new drug application but falls nearly 11%. How do geopolitical issues and AI impacts affect market confidence?

Hong Kong Stock Movement Changfeng Pharmaceutical fell 10.96%. Based on recent key news: On March 16, the new drug clinical trial application for the inhalation powder candidate drug ICF001, independently developed by Changfeng Pharmaceutical, was accepted by the National Medical Products Administration. This news was expected to be positive for the stock price, but the market reaction was not as anticipated, leading to a decline in the stock price. Source: Economic Information Daily On March 16, the Hong Kong stock market continued to experience fluctuations and adjustments due to geopolitical conflicts and other factors. Southbound funds still showed a significant overall net inflow, but failed to effectively support the stock price of Changfeng Pharmaceutical. Source: Yicai Global On March 16, the innovative drug industry faced disruptive impacts from AI technology, and some fund managers maintained a cautious attitude towards the sector's performance, affecting market confidence. Source: Yicai Global. Significant inflow of funds into Hong Kong stocks, with increased volatility. Stocks with High Trading Volume in the Industry CSPC Pharmaceutical Group rose 0.78%. Based on recent key news: On March 17, CSPC Pharmaceutical Group's gene editing research results were published in the journal Science Advances, driving the stock price up. This research provides important evidence for the treatment of transthyretin amyloidosis, enhancing market confidence in the company's R&D capabilities. On March 16, CSPC Pharmaceutical Group's Class 1 new drug SYH2059 inhalation powder received clinical trial approval in China and the United States, raising market expectations for its innovative drugs. This drug targets interstitial lung disease and has significant clinical development value, pushing the stock price higher. On March 16, CSPC Innovative Pharmaceutical announced its performance for the year 2025. Although operating revenue grew by 8.93%, there was a net loss of 241 million yuan, affecting stock price fluctuations. Significant inflow of funds into Hong Kong stocks supports the market. China Biologic Products, with a trading volume of 243 million Hong Kong dollars. Based on recent news: On March 13, China Biologic Products' subsidiary, Zhengda Tianqing, announced that the Center for Drug Evaluation of the National Medical Products Administration has agreed to submit the listing application for TQB3454 tablets for the treatment of advanced IDH1 mutant cholangiocarcinoma. The company plans to submit the application soon. This news boosted market confidence and drove the stock price up. The pharmaceutical industry has performed strongly recently, with clear policy support. Hansoh Pharmaceutical rose 1.54%. Based on recent key news: On March 16, the profitability characteristics of the innovative drug industry were emphasized, with some leading companies already achieving profitability, and more companies expected to enter the profit period in the coming years, driving stock prices up. Source: Yicai Global On March 16, southbound funds continued to flow into Hong Kong stocks, with a cumulative net inflow exceeding 180 billion yuan this year, providing financial support for Hong Kong stocks and boosting market confidence. Source: Yicai Global On March 16, the Hong Kong stock market experienced increased volatility due to geopolitical conflicts, but the support from southbound funds and overseas funds provided structural opportunities for the market. Source: Yicai Global. Hong Kong stocks are supported by southbound funds, with increased volatility Stocks Ranked Among the Top in Industry Market Value Hengrui Medicine rose by 1.62%. Based on recent key news: On March 16, Hengrui Medicine announced that its self-developed innovative drug, Hecolin (Hecolin), has received approval for a new indication for the treatment of patients with severe aplastic anemia. This approval has enhanced market confidence in the company's innovation capabilities, driving the stock price up. Source: Economic Information Daily On March 16, a subsidiary of Hengrui Medicine received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of fumaric acid licorice capsules. This move demonstrates the company's ongoing investment in new drug research and development, boosting investor confidence. Source: Zhitong Finance On March 16, a subsidiary of Hengrui Medicine obtained a clinical trial approval notice for SHR-1819 and SHR-1905 injections, which are planned for the treatment of atopic dermatitis. This progress indicates the company's research and development strength in the biopharmaceutical field, further supporting the rise in stock price. Source: Zhitong Finance The pharmaceutical industry is active in innovative drug research and development, attracting high market attention